Log in

OTCMKTS:NWBO - Northwest Biotherapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
Now: $0.22
50-Day Range
MA: $0.23
52-Week Range
Now: $0.22
Volume834,633 shs
Average Volume716,250 shs
Market Capitalization$132.29 million
P/E RatioN/A
Dividend YieldN/A
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:NWBO
Previous SymbolNASDAQ:NWBO



Sales & Book Value

Annual Sales$410,000.00
Book Value($0.09) per share


Net Income$-35,790,000.00


Market Cap$132.29 million
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter.

Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) issued its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to analysts' expectations of $0.20 million. View Northwest Biotherapeutics' Earnings History.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Northwest Biotherapeutics.

Has Northwest Biotherapeutics been receiving favorable news coverage?

Media coverage about NWBO stock has been trending somewhat positive on Saturday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Northwest Biotherapeutics earned a news sentiment score of 0.6 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Northwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Avid Bioservices (CDMO), Amarin (AMRN), TransEnterix (TRXC), Kura Oncology (KURA), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the folowing people:
  • Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 63)
  • Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 74)
  • Dr. Marnix L. Bosch M.B.A., Ph.D., MBA, Chief Technical Officer (Age 60)
  • Mr. Leslie J. Goldman, Sr. VP & Gen. Counsel (Age 74)
  • Mr. David Innes, VP of Investor Relations

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.22.

How big of a company is Northwest Biotherapeutics?

Northwest Biotherapeutics has a market capitalization of $132.29 million and generates $410,000.00 in revenue each year. Northwest Biotherapeutics employs 14 workers across the globe.View Additional Information About Northwest Biotherapeutics.

What is Northwest Biotherapeutics' official website?

The official website for Northwest Biotherapeutics is http://www.nwbio.com/.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected]

MarketBeat Community Rating for Northwest Biotherapeutics (OTCMKTS NWBO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Northwest Biotherapeutics and other stocks. Vote "Outperform" if you believe NWBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel